Phylogeny, Neoprobe to develop cancer imaging technology
Functional genomic research company Phylogeny and biomedical surgical oncology product provider Neoprobe have entered into a partnership to develop a new imaging technology for head and neck cancers.

Lymphoseek, a radiopharmaceutical developed by Neoprobe that enables imaging of cancer cells within the lymphatic system, will be evaluated for accuracy by Phylogeny. The partners eventually will seek FDA approval for the product, said Columbus, Ohio-based Phylogeny.